Pancreatic cancer is often called the “king of cancers” — one of the deadliest malignancies worldwide. According to the latest statistics, the 5-year survival rate for pancreatic cancer is only about 10%, far lower than other common cancers. Even after patients undergo curative surgical resection (R0 resection), the postoperative recurrence rate remains as high as 70-80%, with most patients experiencing recurrence within 2 years after surgery.
Traditional chemotherapy regimens such as gemcitabine combined with nab-paclitaxel (AG regimen) or FOLFIRINOX, while extending survival for some patients, cause severe side effects that lead many patients to discontinue treatment. For postoperative adjuvant therapy, the current standard is single-agent gemcitabine or capecitabine, but efficacy is limited, and recurrence risk remains high.
In recent years, immunotherapy has achieved breakthrough progress in various solid tumors, but has repeatedly faced setbacks in pancreatic cancer. Pancreatic cancer is considered an “immunologically cold tumor” with sparse T cell infiltration in its tumor microenvironment, and immune checkpoint inhibitor monotherapy is almost ineffective. How to activate anti-tumor immune responses in pancreatic cancer has become a major challenge facing researchers worldwide.
XP-004: An Innovative Vaccine Design
Professor Shen Baiyong’s team at Shanghai Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, collaborated with multiple top domestic medical institutions and biotechnology companies to develop the world’s first personalized mRNA vaccine for pancreatic cancer postoperative adjuvant therapy — XP-004 — after 5 years of research. The vaccine adopts a unique “KRAS universal antigen priming + personalized multi-antigen boosting” strategy and announced stunning Phase I clinical trial data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Core Technical Features
1. KRAS Mutation Universal Antigen Platform
Over 90% of pancreatic cancer patients carry KRAS gene mutations, with G12D, G12V, and G12R being the most common mutation types. The “priming” component of the XP-004 vaccine targets these high-frequency KRAS mutations with universal antigen epitopes, capable of covering the vast majority of pancreatic cancer patients, achieving “off-the-shelf” production that dramatically reduces costs and preparation time.
2. Personalized Neoantigen Boosting Strategy
Each patient’s tumor carries unique gene mutations, and the neoantigens produced by these mutations are key targets for immune system recognition of tumors. The “boosting” component of XP-004 uses high-throughput sequencing and artificial intelligence algorithms to screen the most immunogenic neoantigens from each patient’s tumor tissue and synthesize personalized mRNA sequences. This “universal + personalized” combination strategy ensures both broad vaccine coverage and precise individualized treatment.
3. Optimized mRNA Delivery System
The vaccine uses a novel lipid nanoparticle (LNP) delivery system, which has higher transfection efficiency and better safety compared to traditional vectors. The LNP formulation has been specially optimized to effectively target dendritic cells in lymph nodes, promoting antigen presentation and T cell activation.
Astonishing Clinical Trial Results
The Phase I clinical trial of XP-004 vaccine (NCT056XXXX) enrolled 16 patients with pancreatic ductal adenocarcinoma who underwent R0 resection. These patients were enrolled because they could not tolerate standard chemotherapy. The primary endpoints were safety and immunogenicity, with secondary endpoints including recurrence-free survival (RFS) and overall survival (OS).
Key Data Highlights
100% Recurrence-Free Survival Rate
During a median follow-up of 43.9 weeks (range 24-68 weeks), all 16 patients remained recurrence-free. Considering that the median recurrence time after pancreatic cancer surgery is typically 12-15 months, this result is remarkable. Even compared with historical controls receiving standard adjuvant chemotherapy, XP-004 demonstrated significant advantages.
100% Immune Response Rate
Specific T cell responses against vaccine antigens were detected in all 16 patients. Flow cytometry analysis showed significant expansion of vaccine-induced CD8+ cytotoxic T cells and CD4+ helper T cells, and these T cells could recognize and kill patients’ autologous tumor cells. Importantly, T cell responses against KRAS mutations were detected in all patients, validating the effectiveness of the “universal antigen” strategy.
Excellent Safety Profile
The incidence of ≥ Grade 3 treatment-related adverse events was only 12.5% (2/16), mainly transient self-limiting fever and injection site reactions that resolved without special treatment. No patients withdrew from the trial due to adverse events, and no treatment-related deaths occurred. This safety profile is significantly better than traditional chemotherapy regimens, providing a new treatment option for patients who cannot tolerate chemotherapy.
Durable Immune Memory
During follow-up, vaccine-induced T cell responses showed a continuing upward trend, suggesting the formation of stable immune memory. Some patients still had detectable high levels of tumor-specific T cells 6 months after vaccination, which is crucial for preventing postoperative recurrence.
International Recognition and Impact
The XP-004 vaccine research was selected for oral presentation at the 2026 ASCO Annual Meeting Clinical Science Symposium — the highest-level academic presentation format at ASCO, granted only to research with the most innovation and clinical value. Professor Shen Baiyong detailed the vaccine’s design concept, mechanism of action, and clinical data at the meeting, generating high attention and lively discussion among international peers.
International Expert Comments
Dr. Jennifer Bailey, Pancreatic Cancer Specialist at MD Anderson Cancer Center:
“This is the most important breakthrough in pancreatic cancer immunotherapy in recent years. XP-004’s innovative design cleverly solves the challenge of pancreatic cancer being an immunologically cold tumor. A 100% recurrence-free survival rate is extremely rare in Phase I trials. If this result can be validated in subsequent large-scale trials, it will completely change the standard for pancreatic cancer postoperative adjuvant therapy.”
Prof. Josep Tabernero, Former President of the European Society for Medical Oncology (ESMO):
“Chinese teams have made impressive progress in the field of mRNA cancer vaccines. The ‘universal + personalized’ strategy adopted by XP-004 provides new ideas for treating other immunologically cold tumors and has important reference value. We look forward to seeing this technology’s performance in global multi-center trials.”
Dr. Tetsuya Mitsudomi, Director of the National Cancer Center Research Institute, Japan:
“Postoperative adjuvant therapy for pancreatic cancer has always been a clinical pain point. Traditional chemotherapy has limited benefit and significant toxicity. XP-004 achieved excellent efficacy with extremely low adverse reactions, which is significant for patient populations who cannot tolerate chemotherapy. This research embodies the perfect combination of precision medicine and immunotherapy.”
International Media Attention
The research results have been invited for submission to top journals including Nature Medicine and Journal of Clinical Oncology, with expected formal publication soon. Reuters, Associated Press, and Bloomberg have provided special coverage, calling it a “landmark breakthrough in pancreatic cancer treatment.” The Economist published a long article in its “Science and Technology” section, detailing the innovation and potential impact of this research.
China’s Comprehensive Layout for Pancreatic Cancer Immunotherapy
The success of XP-004 vaccine is not an isolated event, but an important part of China’s systematic layout for pancreatic cancer immunotherapy. In recent years, multiple top Chinese medical institutions and biotechnology companies have conducted comprehensive exploration in the field of pancreatic cancer immunotherapy, forming a complete innovation chain from basic research to clinical translation.
Multi-Dimensional Innovation Layout
1. Novel Vaccine Platforms
- Chinese Academy of Medical Sciences Cancer Hospital is developing dendritic cell (DC)-based pancreatic cancer vaccines, engineering DCs to efficiently present tumor antigens
- The First Affiliated Hospital of Zhejiang University School of Medicine is exploring oncolytic virus combined with vaccine strategies, attempting to convert “immunologically cold tumors” into “immunologically hot tumors”
- Fudan University Shanghai Cancer Center is developing vaccines targeting pancreatic cancer stem cell antigens, aiming to eliminate the root cause of tumor recurrence
2. Combination Therapy Strategies
- Peking University First Hospital is conducting clinical studies of mRNA vaccines combined with immune checkpoint inhibitors, exploring synergistic activation mechanisms
- West China Hospital of Sichuan University is attempting vaccines combined with targeted therapy, dual-targeting the pancreatic cancer stromal barrier
- Sun Yat-sen University Cancer Center has designed vaccine combined with adoptive T cell therapy (ACT) protocols to strengthen anti-tumor immunity
3. New Target Discovery
- National Center for Protein Sciences (Beijing) has discovered multiple pancreatic cancer-specific neoantigens, providing a target library for next-generation vaccine design
- Shanghai Jiao Tong University School of Medicine Systems Biomedicine Institute has revealed new mechanisms of pancreatic cancer immune escape, guiding optimization of combination therapy strategies
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences has developed novel immunomodulators that can enhance vaccine-induced T cell function
4. Industrialization Advancement
- Multiple domestic biotechnology companies have established GMP-standard mRNA vaccine production lines with annual capacity reaching tens of millions of doses
- National Medical Products Administration has accelerated review and approval, opening green channels for innovative cancer vaccines
- Medical insurance departments are exploring outcome-based payment models to promote accessibility of innovative therapies
National Strategic Support
Pancreatic cancer immunotherapy research has been included in the National “14th Five-Year Plan” Key R&D Program “Major Chronic Non-Communicable Disease Prevention and Control” key special project, receiving central government special funding. The Ministry of Science and Technology and National Health Commission jointly released the “Cancer Immunotherapy Innovation and Development Action Plan,” explicitly proposing the goal of achieving 5-10 original cancer vaccines approved for market by 2030. The National Cancer Center led the establishment of the “Pancreatic Cancer Precision Treatment Alliance,” integrating national advantageous resources to promote multi-center clinical research.
Conclusion: Rewriting the Pancreatic Cancer Treatment Landscape
The XP-004 pancreatic cancer mRNA vaccine developed by Professor Shen Baiyong’s team at Shanghai Ruijin Hospital has delivered an astounding answer sheet with 100% recurrence-free survival rate and 100% immune response rate in Phase I clinical trials. This is not only a major breakthrough in China’s cancer immunotherapy field but also an important milestone in the global history of pancreatic cancer treatment.
The success of XP-004 validates the effectiveness of the innovative “KRAS universal antigen + personalized neoantigen” strategy, opening new pathways for treating other immunologically cold tumors. The excellent safety profile makes this vaccine particularly suitable for patient populations who cannot tolerate traditional chemotherapy, filling a gap in clinical treatment.
Currently, Phase II/III randomized controlled clinical trials are being actively prepared, planning to include more centers and international cooperation to further validate efficacy and safety. If large-scale trials can replicate the excellent results of Phase I, XP-004 is expected to be approved for market within 3-5 years, becoming the new standard for pancreatic cancer postoperative adjuvant therapy.
More importantly, this achievement demonstrates that China’s innovation capability in cancer immunotherapy has reached the world’s forefront. From target discovery, vaccine design, clinical research to industrialization, China is building a complete innovation chain, contributing Chinese wisdom and Chinese solutions to global cancer patients.
The treatment landscape for pancreatic cancer is being rewritten, and the starting point of this transformation is precisely this breakthrough research at Shanghai Ruijin Hospital. We have reason to believe that in the near future, pancreatic cancer will no longer be the “king of cancers,” and patients will welcome true hope for cure.